388 related articles for article (PubMed ID: 32705582)
1. Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.
Dash D; Mestre TA
Neurotherapeutics; 2020 Oct; 17(4):1645-1659. PubMed ID: 32705582
[TBL] [Abstract][Full Text] [Related]
2. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
3. Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.
Tabrizi SJ; Ghosh R; Leavitt BR
Neuron; 2019 Mar; 101(5):801-819. PubMed ID: 30844400
[TBL] [Abstract][Full Text] [Related]
4. Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic.
Rook ME; Southwell AL
BioDrugs; 2022 Mar; 36(2):105-119. PubMed ID: 35254632
[TBL] [Abstract][Full Text] [Related]
5. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the therapeutic development for Huntington disease.
Mestre TA
Parkinsonism Relat Disord; 2019 Feb; 59():125-130. PubMed ID: 30616867
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies for Huntington's disease.
Estevez-Fraga C; Flower MD; Tabrizi SJ
Curr Opin Neurol; 2020 Aug; 33(4):508-518. PubMed ID: 32657893
[TBL] [Abstract][Full Text] [Related]
8. Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study.
Liu H; Zhang C; Xu J; Jin J; Cheng L; Miao X; Wu Q; Wei Z; Liu P; Lu H; van Zijl PCM; Ross CA; Hua J; Duan W
Brain; 2021 Nov; 144(10):3101-3113. PubMed ID: 34043007
[TBL] [Abstract][Full Text] [Related]
9. Nucleic Acid Therapeutics in Huntington's Disease.
Singh K; Roy I
Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
[TBL] [Abstract][Full Text] [Related]
10. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion.
Keller CG; Shin Y; Monteys AM; Renaud N; Beibel M; Teider N; Peters T; Faller T; St-Cyr S; Knehr J; Roma G; Reyes A; Hild M; Lukashev D; Theil D; Dales N; Cha JH; Borowsky B; Dolmetsch R; Davidson BL; Sivasankaran R
Nat Commun; 2022 Mar; 13(1):1150. PubMed ID: 35241644
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies in Huntington's disease.
Bashir H
Expert Rev Neurother; 2019 Oct; 19(10):983-995. PubMed ID: 31181964
[No Abstract] [Full Text] [Related]
12. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
Miniarikova J; Evers MM; Konstantinova P
Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
[TBL] [Abstract][Full Text] [Related]
13. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.
Tabrizi SJ; Estevez-Fraga C; van Roon-Mom WMC; Flower MD; Scahill RI; Wild EJ; Muñoz-Sanjuan I; Sampaio C; Rosser AE; Leavitt BR
Lancet Neurol; 2022 Jul; 21(7):645-658. PubMed ID: 35716694
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease.
Kay C; Collins JA; Caron NS; Agostinho LA; Findlay-Black H; Casal L; Sumathipala D; Dissanayake VHW; Cornejo-Olivas M; Baine F; Krause A; Greenberg JL; Paiva CLA; Squitieri F; Hayden MR
Am J Hum Genet; 2019 Dec; 105(6):1112-1125. PubMed ID: 31708117
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of Huntington's disease: Molecular and clinical approaches.
Kumar D; Hasan GM; Islam A; Hassan MI
Biochem Biophys Res Commun; 2023 May; 655():18-24. PubMed ID: 36913762
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
[TBL] [Abstract][Full Text] [Related]
17. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
[TBL] [Abstract][Full Text] [Related]
18. Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks.
Leavitt BR; Kordasiewicz HB; Schobel SA
JAMA Neurol; 2020 Jun; 77(6):764-772. PubMed ID: 32202594
[TBL] [Abstract][Full Text] [Related]
19. [Gene-selective treatment approaches for Huntington's disease].
Mühlbäck A; Lindenberg KS; Saft C; Priller J; Landwehrmeyer GB
Nervenarzt; 2020 Apr; 91(4):303-311. PubMed ID: 32179957
[TBL] [Abstract][Full Text] [Related]
20. Delivering a disease-modifying treatment for Huntington's disease.
Godinho BM; Malhotra M; O'Driscoll CM; Cryan JF
Drug Discov Today; 2015 Jan; 20(1):50-64. PubMed ID: 25256777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]